Park Avenue Securities LLC Buys 3,696 Shares of Johnson & Johnson (NYSE:JNJ)

Park Avenue Securities LLC increased its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 12.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,489 shares of the company’s stock after buying an additional 3,696 shares during the period. Park Avenue Securities LLC’s holdings in Johnson & Johnson were worth $5,634,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. Legal & General Group Plc raised its stake in Johnson & Johnson by 2.3% in the second quarter. Legal & General Group Plc now owns 18,839,914 shares of the company’s stock valued at $3,344,295,000 after buying an additional 421,779 shares during the period. FMR LLC lifted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 1.9% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after acquiring an additional 328,297 shares during the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in Johnson & Johnson by 0.3% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,163,229 shares of the company’s stock valued at $1,333,545,000 after acquiring an additional 24,505 shares during the period. 67.94% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the business’s stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now directly owns 41,813 shares in the company, valued at $7,336,927.11. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 76,923 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares of the company’s stock, valued at approximately $22,354,891.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the transaction, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 233,611 shares of company stock valued at $40,960,735. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price objective on the stock. Atlantic Securities lowered their price target on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Sanford C. Bernstein reduced their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James lowered their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Finally, Bank of America decreased their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Stock Down 0.5 %

Shares of NYSE JNJ opened at $168.74 on Monday. The stock has a market capitalization of $441.17 billion, a P/E ratio of 23.50, a PEG ratio of 3.19 and a beta of 0.56. The stock’s fifty day moving average is $176.14 and its 200 day moving average is $171.20. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.68%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s payout ratio is presently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.